Shares of Prestige Consumer Healthcare Inc. (NYSE: PBH) have received a consensus rating of “Hold” from analysts covering the company, according to MarketBeat.com. This assessment comes from a total of seven brokerages, with one analyst issuing a sell rating, two maintaining hold ratings, and four assigning buy ratings. The average target price for the stock over the next year is set at $94.80.
Recent reports from various equities research analysts indicate shifting perspectives on Prestige Consumer Healthcare. On September 4, Zacks Research downgraded the company from a hold to a strong sell rating. Conversely, Weiss Ratings reaffirmed its hold rating on September 27. Notably, on September 24, Sidoti upgraded its rating from neutral to buy, setting a target price of $80.00. In a separate report on August 8, Canaccord Genuity Group reduced its target from $105.00 to $100.00 while maintaining a buy rating. Following that, on August 9, Wall Street Zen adjusted its rating from buy to hold.
Institutional Investments and Market Performance
In terms of institutional investments, several significant investors have recently adjusted their holdings in Prestige Consumer Healthcare. Cerity Partners LLC increased its stake by 3.7% in the first quarter, now owning 3,666 shares valued at $315,000. UMB Bank n.a. significantly raised its position by 81.8% in the second quarter, acquiring 320 shares now valued at $26,000.
Additionally, KBC Group NV grew its stake by 7.4% in the first quarter, bringing its total to 2,199 shares worth $189,000. Bank of Montreal Can also increased its holdings by 2.0%, owning now 9,351 shares valued at $747,000. Meanwhile, Xponance Inc. raised its stake by 5.5%, now controlling 3,766 shares valued at $324,000. Collectively, institutional investors and hedge funds hold approximately 99.95% of the company’s stock.
On the market front, shares of Prestige Consumer Healthcare opened at $62.85 on Friday. The company’s fifty-day moving average price is $65.99, while the two-hundred-day moving average stands at $76.62. Prestige maintains a market capitalization of $3.09 billion and reports a P/E ratio of 14.75 with a beta of 0.44. The company has experienced a one-year low of $61.28 and a high of $90.04.
Recent Financial Performance
The last earnings report from Prestige Consumer Healthcare was released on August 7, revealing earnings per share (EPS) of $0.95, which fell short of analysts’ expectations of $1.01 by $0.06. The company reported revenue of $249.53 million, lower than the anticipated $260.71 million. This performance reflects a 6.6% decrease in revenue year-over-year, compared to an EPS of $0.90 in the same period last year.
Looking ahead, Prestige Consumer Healthcare has set guidance for fiscal year 2026 at an EPS range of $4.500 to $4.580. Analysts forecast an EPS of $4.5 for the current year, indicating cautious optimism for the company’s financial recovery.
Founded with a focus on developing, manufacturing, and distributing over-the-counter health and personal care products, Prestige Consumer Healthcare operates primarily in the North American and international markets. As the company navigates a fluctuating stock market and evolving industry landscape, the upcoming months will be crucial in determining its growth trajectory and investor confidence.
